Recombinant Factor IX

Gilbert C White II; Aime Beebe; Brenda Nielsen

doi:10.1055/s-0038-1657536

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1997; 78(01): 261-265
DOI: 10.1055/s-0038-1657536

New recombinant products in the treatment of hemophilias

Schattauer GmbH Stuttgart

Recombinant Factor IX

Gilbert C White II

Departments of Medicine and Pharmacology, Center for Thrombosis and Hemostasis, Comprehensive Hemophilia Diagnosis and Treatment Center, University of North Carolina, Chapel Hill, NC, USA

,

Aime Beebe

Departments of Medicine and Pharmacology, Center for Thrombosis and Hemostasis, Comprehensive Hemophilia Diagnosis and Treatment Center, University of North Carolina, Chapel Hill, NC, USA

,

Brenda Nielsen

Departments of Medicine and Pharmacology, Center for Thrombosis and Hemostasis, Comprehensive Hemophilia Diagnosis and Treatment Center, University of North Carolina, Chapel Hill, NC, USA

› Author Affiliations

Abstract

PDF Download

PDF (1176 kb)

References

References
1 Nishimura H, Kawahata II S, Kisiel W, Hase S, Ikenaka T, Takao T, Shimonishi Y, Iwanaga S. Identification of a disaccharide (Xyl-Glc) and a trisaccharide (Xyl₂-Glc) O-glycosidically linked to a serine residue in the first epidermal growth factor-like domain of human factors VII and IX and protein Z and bovine protein Z. J Biol Chem 1989; 264: 20320-20325
2 Jorgensen MJ, Cantor AB, Furie BC, Brown CL, Shoemaker CB, Furie B. Recognition site directing vitamin K-dependent γ-carboxylation residues in the propeptide of factor IX. Cell 1987; 48: 185-191
3 Wasley LC, Rehemtulla A, Bristol JA, Kaufman RJ. Pace/furin can process the vitamin K-dependent pro-factor IX precursor within the secretory pathway. J Biol Chem 1993; 268: 8458-8465
4 Femlund P, Stenflo J. β-Hydroxyaspartic acid in vitamin K-depedent proteins. J Biol Chem 1983; 258: 12509-12512
5 Mannucci PM. Outbreak of hepatitis A among Italian patients with haemophilia. Lancet 1992; 339: 819
6 Gerritzen A, Schneweis KE, Brackman H-H, Oldenburg J, Hanfland P, Gerlich WH, Caspari G. Acute hepatitis A in haemophiliacs. Lancet 1992; 340: 1231-1232
7 Mariani G, di PaolantonioT, Baklaya R, Morfmi M, Mannucci PM. Prospective study of the evaluation of hepatitis C virus infectivity in a high-purity, solvent/detergent treated factor VIII concentrate: Parallel evaluation of other markers for lipid-enveloped and non-lipid-enveloped viruses. Transfusion 1993; 33: 814-818
8 Flores G, Juarez JC, Montoro JB. et al. Seroprevalence of parvovirus B19, cytomegalovirus, hepatitis A virus and hepatitis E virus antibodies in haemophiliacs treated exclusively with clotting-factor concentrates considered safe against human immunodeficiency and hepatitis C viruses. Haemophilia 1995; 01: 115-117
9 Hepatitis A among persons with hemophilia who received clotting factor concentrate-United States. 09 1995; MMWR (Atlanta, Ga: Centers for Disease Control. US Department of Health and Human Services publication). 1996; 45: 29-32
10 Yee TT, Cohen BJ, Pasi KJ, Lee CA. Transmission of symptomatic parvovirus B19 infection by clotting factor concentrate. Brit J Haemat 1996; 93: 457-459
11 Ragni MV, Koch WC, Jordan JA. Parvovirus B19 infection in patients with hemophilia. Transfusion 1996; 36: 238-241
12 Kaufman RJ, Wasley LC, Furie BC, Furie B, Shoemaker CB. Expression, purification, and characterization of recombinant ϒ-carboxylated factor IX synthesized in Chinese hamster ovary cells. J Biol Chem 1986; 261: 9622-9628
13 Bond MD, Patel H, Huberty MC. et al: Structural and biological characterization of Gla-related isoforms of recombinant human factor IX shows that Gla36 and Gla40 are not essential forin vitrolotting activity. Thrombos Haemostas 1995; 73: 1167-1168
14 Gillis S, Furie BC, Furie B, Patel H, Huberty MC, Switzer M, Foster WB, Scoble HA, Bond MD. y-Carboxyglutamic acids 36 and 40 do not contribute to human factor IX function. Protein Sci 1997; 06: 185-196
15 Brinkhous KM, Sigman JL, Read MS, Stewart PF, McCarthy KP, Timony GA, Lappanen SD, Rup BJ, Keith Jr JC, Garzone PD, Schaub RG. Recombinant factor IX: Replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B. Blood 1996; 88: 2803-2810
16 Kim HC, McMillan CW, White II GC, Horton MW, Saidi P. Purified factor IX using monoclonal immunoaffinity technique: Clinical trials in hemophilia B and comparison to prothrombin complex concentrates. Blood 1992; 79: 568-575
17 Goldsmith JC, Kasper CK, Blatt PM, Gomperts ED, Kessler CM, Thompson AR, Herring SW, Novak PL. Coagulation factor IX: Successful surgical experience with a purified factor IX concentrate. Am J Hemat 1992; 40: 210-215
18 Bemtorp E, Björkman S, Carlsson M, Lethagen S, Nilsson IM. Biochemical and in vivo properties of high purity factor IX concentrates. Thrombos Haemostas 1993; 70: 768-773
19 Poon M-C, Aledort LM, Anderle K, Kunschak M, Morfmi M. Comparison of the recovery and half-life of a high purity factor IX concentrate with those of a factor IX complex concentrate. Transfusion 1995; 35: 319-323